肿瘤细胞治疗研究
ALL SOURCES
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer.
本研究开发的串联双特异性 CAR-NK92 细胞代表了免疫治疗领域的一项有意义进展。
Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer.
CD155 成为 OC 中 CAR-T 疗法一个有前景的治疗靶点。
Combined CHK1 and PD-L1 blockade as a novel therapeutic strategy against stemness and immunosuppression in ovarian cancer.
双重靶向 CHK1 和 PD-L1 可能通过同时抑制干性和增强抗肿瘤免疫来改善 OC 治疗。
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
上皮性卵巢癌是致死率最高的妇科癌症。
Advancements in CAR-T Cell Therapy for Ovarian Cancer: Current Strategies and Future Directions.
嵌合抗原受体（CAR）T 细胞疗法已成为肿瘤学中的一种变革性方法，尤其在血液系统恶性肿瘤中。
Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
上皮性卵巢癌是妇科癌症中最致命的一种。
共 7 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
